logo
F.D.A. Panel Debates ‘Black Box' Warning for Antidepressants in Pregnancy

F.D.A. Panel Debates ‘Black Box' Warning for Antidepressants in Pregnancy

New York Times3 days ago
Over nearly four decades since Prozac was approved for the treatment of depression, waves of concern about the effects of antidepressants during pregnancy have resulted in a practical consensus: Though use of the drugs may be associated with a slight rise in the odds of birth defects, the risk of leaving a mother's depression untreated is often greater.
But a high-level shift is taking place within the Department of Health and Human Services under Secretary Robert F. Kennedy Jr., who has made reducing the prescription of psychotropic drugs a policy priority.
Among the select group of experts convened by the Food and Drug Administration on Monday to discuss the safety of antidepressants during pregnancy, around half said that women should receive a more clear and forceful warning about potential risks to the fetus.
Andrew Nixon, an H.H.S. spokesman, said the agency would not comment on whether there were plans to require a so-called black box warning about the use of selective serotonin reuptake inhibitors, or S.S.R.I.s, in pregnancy.
In his introductory remarks, F.D.A. commissioner Dr. Marty Makary said that 'some women are not aware' of the risks of taking antidepressants in pregnancy, suggesting openness to the idea. Around 5 percent of pregnant American women take antidepressants, he said.
'Serotonin might play a crucial role in the development of organs of a baby in utero,' Dr. Makary said.
Want all of The Times? Subscribe.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Antisense & RNAi Therapeutics Market Outlook 2025-2033: Advancements in Drug Delivery Propel Growth with Revenues Forecast to Reach $3.3 Billion by 2033
Antisense & RNAi Therapeutics Market Outlook 2025-2033: Advancements in Drug Delivery Propel Growth with Revenues Forecast to Reach $3.3 Billion by 2033

Yahoo

time29 minutes ago

  • Yahoo

Antisense & RNAi Therapeutics Market Outlook 2025-2033: Advancements in Drug Delivery Propel Growth with Revenues Forecast to Reach $3.3 Billion by 2033

Antisense & RNAi Therapeutics Market Dublin, July 25, 2025 (GLOBE NEWSWIRE) -- The "Antisense & RNAi Therapeutics Market by Technology, Route of Administration, Application, and Region 2025-2033" has been added to offering. The global antisense & RNAi therapeutics market is poised for significant growth, with the market size projected to rise from USD 1.8 Billion in 2024 to USD 3.3 Billion by 2033, at a CAGR of 7.03% from 2025 to 2033. This growth is driven by a high prevalence of genetic and chronic diseases, supportive regulatory environments, and technological advancements in drug delivery systems. Antisense & RNAi Therapeutics Market Analysis: Major Market Drivers: Technological advancements in drug delivery systems and the prevalence of genetic disorders and chronic diseases. Key Market Trends: Personalized medicine and improved patient outcomes. Geographical Trends: North America leads the market due to its robust healthcare infrastructure and regulatory support. Competitive Landscape: A dynamic market featuring traditional pharmaceutical giants and innovative newcomers battling for patents and regulatory approvals. Challenges and Opportunities: High development costs present both obstacles and opportunities for innovation. Technological Advancements in Drug Delivery Technologies that improve RNA molecule delivery have become a major driver, enhancing efficacy in targeting specific cells. Lipid nanoparticles and conjugate technologies exemplify how delivery has improved, particularly for cancer and viral infections. Increasing Prevalence of Genetic Disorders The growing incidence of genetic and chronic diseases propels market growth. These therapeutics represent new treatment avenues, particularly for conditions unmanageable with conventional methods, fueling investment in biopharmaceutical R&D. Supportive Regulatory Environment Regulatory incentives, such as orphan drug status and faster review processes, are pivotal in driving market demand. For instance, the FDA's support enhances RNAi and antisense development. Market Segmentation Technology: RNA Interference, siRNA, miRNA, Antisense RNA Route of Administration: Includes intravenous, subcutaneous, and pulmonary delivery, with the latter holding the largest share due to its efficacy in respiratory treatments. Application: Oncology, cardiovascular diseases, respiratory disorders, and more. Region: North America leads, supported by its biotechnological infrastructure and the prevalence of target diseases. Competitive Landscape Key players like Alnylam Pharmaceuticals and Ionis Pharmaceuticals are increasing their R&D investments, engaging in strategic acquisitions and partnerships to harness emerging technologies. This strategy not only enhances their competitive edge but also accelerates the introduction of new RNA-based therapies to the market. Key Questions Answered in This Report: Market size and expected growth rate from 2025 to 2033? Key factors driving market growth? Impact of COVID-19 on the market? Technology and route of administration breakdowns? Leading regions and key players in the market? Key Attributes Report Attribute Details No. of Pages 135 Forecast Period 2024-2033 Estimated Market Value (USD) in 2024 $1.8 Billion Forecasted Market Value (USD) by 2033 $3.3 Billion Compound Annual Growth Rate 7% Regions Covered Global Key Topics Covered 1 Preface 2 Scope and Methodology 2.1 Objectives of the Study 2.2 Stakeholders 2.3 Data Sources 2.3.1 Primary Sources 2.3.2 Secondary Sources 2.4 Market Estimation 2.4.1 Bottom-Up Approach 2.4.2 Top-Down Approach 2.5 Forecasting Methodology 3 Executive Summary 4 Introduction 4.1 Overview 4.2 Key Industry Trends 5 Global Antisense & RNAi Therapeutics Market 5.1 Market Overview 5.2 Market Performance 5.3 Impact of COVID-19 5.4 Market Forecast 6 Market Breakup by Technology 6.1 RNA Interference 6.2 Antisense RNA 7 Market Breakup by Route of Administration 7.1 Intravenous Route 7.2 Subcutaneous Route 7.3 Intrathecal Route 7.4 Pulmonary Delivery 7.5 Intraperitoneal Injection 7.6 Others 8 Market Breakup by Application 8.1 Oncology 8.2 Cardiovascular Diseases (CVDs) 8.3 Respiratory Disorders 8.4 Renal Diseases 8.5 Neurodegenerative Disorders 8.6 Genetic Disorders 8.7 Infectious Diseases 8.8 Others 9 Market Breakup by Region 9.1 North America 9.2 Asia-Pacific 9.3 Europe 9.4 Latin America 9.5 Middle East and Africa 10 SWOT Analysis 11 Value Chain Analysis 12 Porters Five Forces Analysis 13 Price Analysis 14 Competitive Landscape Companies Featured Alnylam Pharmaceuticals Inc. Arbutus Biopharma Corporation Arrowhead Pharmaceuticals Inc. Benitec Biopharma Ltd. Bio-Path Holdings Inc. Dicerna Pharmaceuticals Inc. (Novo Nordisk A/S) Ionis Pharmaceuticals Inc. OliX Pharmaceuticals Inc. Phio Pharmaceuticals Corp. Sarepta Therapeutics Inc. Silence Therapeutics Sirnaomics Inc. For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Antisense & RNAi Therapeutics Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

Why Are RSV Vaccine Rates so Shockingly Low?
Why Are RSV Vaccine Rates so Shockingly Low?

Medscape

time3 hours ago

  • Medscape

Why Are RSV Vaccine Rates so Shockingly Low?

Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infections in infants and children younger than 2 years. The most severe and life-threatening cases typically affect infants younger than 6 months. However, older toddlers, adults with chronic illnesses or multiple comorbidities, and older adults are also at an elevated risk. Immunization Progress Research on both active and passive RSV immunization has advanced significantly in recent years. Following the approval of the first prophylactic antibody in 2022 and two vaccines in 2023, the prevention of severe RSV illnesses has become increasingly effective. Current strategies include maternal vaccination to protect newborns, immunization of older adults, and passive immunization of infants using the monoclonal antibody nirsevimab. In June, the FDA approved a second monoclonal antibody: clesrovimab. Nirsevimab Nirsevimab (Beyfortus) has been available in the European Union since November 2022. It is indicated for RSV prophylaxis in all infants during their first RSV season and in children up to 2 years of age who are at increased risk during their second season. Nirsevimab is a human monoclonal immunoglobulin G1 (IgG1) kappa antibody produced using recombinant DNA technology. It binds to a highly conserved site on the RSV fusion (F) glycoprotein, which is present only in the prefusion form of the viral surface protein. Nirsevimab has a markedly longer serum half-life than earlier antibodies. The drug is administered as a single intramuscular dose adjusted according to the child's weight. Germany's Standing Committee on Vaccination recommends that infants born between April and September receive antibodies in autumn before their first RSV season. Those born between October and March should receive the vaccine as soon as possible after birth. Clesrovimab Clesrovimab (Enflonsia) is a human monoclonal IgG1 kappa antibody. Unlike nirsevimab, it binds to two sites in both the pre- and post-fusion conformations of the F protein. It is administered as a single intramuscular injection and does not require weight-based dosing. The manufacturer has applied for approval from the European Medicines Agency, and the decision is pending. RSV Vaccines Three RSV vaccines, each targeting a different group, are currently authorized for use in Germany. Arexvy: A monovalent recombinant protein vaccine that includes the RSV F protein and the AS01E adjuvant. It is approved for adults aged 60 years or older. Abrysvo: A bivalent recombinant protein vaccine containing prefusion F antigens from RSV subtypes A and B. It is authorized for use in pregnant women to protect their infants up to 6 months of age and in adults aged 60 years or older. mResvia: Approved in mid-2024, this is the only mRNA RSV vaccine currently available. It is indicated for adults aged 60 years or older and was recently approved in the US for high-risk adults aged 18-59 years. Real-World Data Although clinical trials have demonstrated the strong efficacy of RSV vaccines and antibodies in preventing severe illnesses, data from real-world immunization programs are limited. A new systematic review by UK researchers addressed this gap. Between December 2024 and February 2025, they conducted monthly searches across the Ovid, Embase, MEDLINE, and global health databases. The review included 43 studies that evaluated nirsevimab, maternal RSV vaccination, and adult RSV vaccination. The goal was to assess uptake across countries and demographic groups. Data from more than 1.38 million individuals in Spain, France, Italy, Luxembourg, and the US were analyzed. One study combined records from Catalonia and Andorra. Most data (86%) were drawn from electronic health records and medical registries, and vaccine data were solely from the US. Nirsevimab Uptake In Spain, the uptake of nirsevimab during the 2023-2024 RSV season reached 90.1% (95% CI, 86.4-92.9), the highest of any country reviewed. Infants born during the RSV season and Spanish nationals had higher immunization rates. In the US, 51.2% of eligible infants received nirsevimab in 2023-2024. Uptake was greater among preterm infants, those with at least one comorbidity, and those from Hispanic backgrounds. France recorded 76.5% coverage, with higher rates in infants younger than 3 months than in those aged 3-12 months. Luxembourg reported 83.8%, Italy 68.7%, and Catalonia-Andorra combined 60.2%. Subgroup analyses revealed that children who experienced RSV or other acute respiratory infections were less likely to receive nirsevimab. Maternal Vaccination Maternal RSV vaccine coverage during pregnancy was 30.5% (95% CI, 20.6-42.6). Uptake was significantly lower among women without health insurance or with statutory coverage than among those with private insurance. Black and Hispanic women had lower rates than non-Hispanic White women. Older Adult Vaccination Four population-based studies assessed RSV vaccine uptake in adults aged 60 years or older, showing an average rate of 18.2% (95% CI, 10.8-28.9) in 2023-2024. Uptake was higher among adults older than 75 years, those with comorbidities, and immunocompromised individuals. As with maternal vaccination, the rates were lower among the Black and Hispanic populations. The researchers highlighted the concerningly low uptake among pregnant women and older adults despite the availability of effective prevention tools. They called for coordinated national, clinical, and public health efforts to improve immunization rates in high-risk populations. World Health Organization (WHO) Guidance In May, the WHO published its first position paper on RSV immunization in infants and young children, underscoring global urgency. RSV is the leading cause of pediatric morbidity and mortality. In 2019, an estimated 100,000 children younger than 5 years died from RSV-related lower respiratory tract infections, representing about 2% of all deaths in this age group. Approximately half of these deaths occur in infants younger than 5 months, with 97% occurring in low- and middle-income countries. Globally, RSV accounts for an estimated 3.6 million hospitalizations annually in children younger than 5 years. The WHO recommends that all countries implement immunization programs to prevent severe RSV disease in vulnerable groups. The choice between maternal vaccination and the use of long-acting monoclonal antibodies, such as nirsevimab, should be based on local factors, including health system integration, cost, and overall feasibility. Germany's Robert Koch Institute provides additional guidance in its fact sheets on RSV immunization, including details on nirsevimab and adult vaccinations.

NextCure presents new preclinical data on osteogenesis imperfecta treatment
NextCure presents new preclinical data on osteogenesis imperfecta treatment

Business Insider

time5 hours ago

  • Business Insider

NextCure presents new preclinical data on osteogenesis imperfecta treatment

NextCure (NXTC) announced the presentation of new preclinical data in a well-established model of osteogenesis imperfecta demonstrating that treatment with NC605, a novel anti-Siglec-15 antibody, achieved improved bone microarchitecture and reduced fracture incidence compared to anti-sclerostin treatment. The data were presented at the Brittle Bone Society Meeting on July 24th, 2025. These results demonstrate that NC605 could be a highly effective treatment for OI, also known as brittle bone disease. OI is a rare disorder that results in high bone turnover, abnormal bone formation, bone fragility and recurrent fractures. There is no cure for OI. Current anti-resorptive treatments inhibit both bone loss and bone formation leading to an increase in bone density, but overall poor bone quality. In contrast, NC605 has been shown to inhibit bone loss and to produce new bone, with increased quality and density. Fracture incidence and bone architecture were assessed in male and female OI mice treated with weekly 20 mg/kg of surrogate antibody NP159 and compared to control groups treated with twice weekly 50 mg/kg anti-sclerostin or saline. NP159 increased cortical and trabecular bone mineral density, tissue mineral density, cortical thickness and decreased trabecular separation compared to saline-treated mice. 'In a mouse model of moderate-to-severe OI, NP159, a surrogate murine antibody for NC605, improved trabecular and cortical bone density and reduced fracture incidence comparable to anti-sclerostin,' said Priyanka Kothari, Ph.D., NextCure's Director, Translational Research. 'There is currently no standard of care approved by the FDA for patients with OI and NC605 has the potential to provide significant therapeutic benefit for patients.'

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store